ABSTRACT TOPICS:

- Epidemiology, comorbidity, outcomes and classification, including big data
- General and organisational aspects of headache care
  - Telemedicine
  - E-tools
- Genetics and biomarkers of headache disorders
- Headache Pathophysiology: Basic Research
- Headache Pathophysiology: Clinical Research
- Headache Pathophysiology: Imaging
- Migraine – acute therapy: Pharmacological and Device based
- Migraine – preventive therapy: Pharmacological and Device based
- Cluster headache and other TACs
- Tension-type headache and other primary headaches (in line with ICHD-3 terminology ‘4. other primary headache disorders’)
- Medication overuse headache
- Post-traumatic headache, COVID-associated headache
- Idiopathic intracranial hypertension
- Other secondary headaches
- Paediatric headache
- Post-traumatic headache
- Psychological and behaviour factors

MTIS 2022 MEETING GUIDELINES

Please read this information carefully before proceeding to the online submission form.

IMPORTANT DATES

- Submissions accepted from: 1 March 2022
- Submission deadline: 1 June 2022, Midday (UK time)
- Abstracts Review: June 2022
- Late breaking abstracts: There will be a chance to submit ‘late breaking’ abstracts from 4 July 2022 for two weeks – Details of this will follow in due course

Abstracts received after the deadlines will not be accepted!

TECHNICAL REQUIREMENTS

The internet abstract submission system works best with Internet Explorer 8.0 or higher, Mozilla Firefox 5.0 or higher and Chrome 16 or higher. Cookies and JavaScript need to be enabled.
GENERAL

1. Abstracts can only be submitted online via the online abstract submission form that can be found in the section “ABSTRACTS” on the official Migraine Trust International Symposium website: http://mtis2022.org/

2. Abstracts must be submitted in English.

3. Abstracts sent by post or email will not be accepted. No exceptions will be made.

DEFINITIONS

- Submitting author: person who submits the abstract
- Presenting author: person who will physically present the abstract at the congress and who is marked as the presenter in the programme.

RULES

Failure to observe these guidelines may result in disqualification.


2. An abstract can be submitted to the Migraine Trust International Symposium if it has not been published previously and only presented at a national meeting.

3. The correct topic must be selected to ensure correct scoring. The content of the abstract must be topic related.

4. Abstracts must contain data and meet international ethical standards.

5. Abbreviations should be defined.

6. Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body of the text.

7. An abstract cannot be accepted if the conflict of interest disclosure has not been ticked on the submission form. If the research or one of the co-authors has a conflict of interest, this must be clearly stated.

8. The abstract cannot contain more than 3,000 characters (approx. 500 words) (blank spaces, punctuation as well as authors affiliation and titles included).

9. The abstract must be structured into the following sections:
   - Introduction
   - Objectives
   - Methods
10. One table can be included, with the following restrictions:

Max number of columns: 10
Max number of rows: 10
Please note that tables may significantly reduce the number of available characters.

One image can be included, with the following restrictions:

Width: Min: 50 Max: 750
Height: Min: 50 Max: 750
Size: Min: 15 Max: 750
DPI: Min: 96 Max: 750

11. Abstracts can be saved in “DRAFT” status to be re-edited and modified until the submission deadline (1 June 2022, Midday UK time). The submitting author will be required to create a user account. In order to log back into the portal please make a note of the username and password created during the process.

12. If you have successfully submitted your abstract, you will receive a confirmation number. If no confirmation number is received, the abstract cannot be considered as successfully submitted and accepted.

13. Abstracts fulfilling all criteria can be saved in “FINAL SUBMISSION” status. Only abstracts in “FINAL SUBMISSION” status will be considered as successfully submitted and accepted.

14. If you leave the system without saving the abstract all data is lost. The submitted/draft abstracts cannot be edited after the submission deadline (1 June 2022, Midday UK time).

15. Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are possible after the submission deadline. The abstract will be reproduced exactly as submitted. No proof reading will be done.

16. If you need to withdraw your abstract, a written statement reflecting the reasons for this decision must be sent to: MTIS2022Abstracts@mci-group.com no later than Monday 11 July 2022.

AFTER THE SUBMISSION

1. The reviewers will judge the abstracts according to the relevance to MTIS2022. They will assess the standard of English, objectivity of statements, description of the work, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.

2. The submitting author will be notified during the first week of July whether the abstract has been accepted. Notifications will be sent via email to the email address provided during submission. It is the submitting authors’ responsibility to ensure that emails from MTIS2022 can reach them. Within the notification authors will be informed of the date, time and form of the presentation.
PUBLICATION POLICY

All abstracts accepted for presentation (oral or poster) will be published in digital format within the official abstract book of the meeting. The abstracts for the Migraine Trust International Symposium will also be published online, and in *Cephalalgia*. All abstracts accepted for presentation at MTIS2022 will be included within the event app. Please note that Cephalalgia will hold the copyright of all accepted abstracts.

PRESENTATION OF ABSTRACTS

1. Abstracts can be accepted either as a poster, e-poster or oral presentation.

2. If your abstract is accepted as a poster, you will be requested to be available for discussion during the corresponding moderated poster viewing session.

3. Authors presenting their abstract as e-posters will be provided with details on how to upload content to the platform.

4. Oral presenters will be advised of presentation date and length of presentation once the abstract has been accepted.

5. Full presentation guidelines will be included in the acceptance letter and posted on the conference website.

PROBLEMS SUBMITTING?

If you experience any kind of problem or if you have questions, please do not hesitate to contact the abstract management team on the contact details below:

Phone: +44 (0) 1730 715 274
Email: MTIS2022Abstracts@mci-group.com

Contact us

General enquiries tel: +44 (0) 1730 715 243

General information:
MTIS2022@mci-group.com